Project Grant R01CA300076
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $624K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
- Federal Grant Award Summary The University of Rochester received a $639,098 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and concluding July 31, 2030. This award supports research targeting intrinsic and extrinsic barriers to metastatic pancreatic ductal adenocarcinoma (PDAC) treatment. The project develops and evaluates an innovative combination therapy approach designed to overcome treatment resistance...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Rochester a Project Grant valued at $388,901 under the Cancer Biology Research program (CFDA 93.396) to investigate the role of transcriptional co-activator PGC-1A in promoting anti-tumor immunity in colorectal cancer (CRC). The research, which commenced June 5, 2026 and concludes May 31, 2028, focuses on understanding how PGC-1A activation can enhance immune responses against CRC tumors, particularly in...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a Project Grant totaling $408,829 under the Cancer Treatment Research program (CFDA 93.395) to investigate lipogenesis-mediated resistance to cytotoxic therapy in pancreatic ductal adenocarcinoma (PDAC). The award, effective May 25, 2026 through April 30, 2028, supports fundamental research aimed at characterizing how tumor cells use de novo lipid production to escape cell death mechanisms and evade...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary Georgetown University received a $401,115 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on May 7, 2026, with a completion date of April 30, 2028. The award supports research into innovative therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), a disease with a poor prognosis and limited treatment response to current chemotherapy and immunotherapy regimens. The research...
- Federal Project Grant Award Summary The University of Rochester received a $345,413 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 10, 2026, with a completion date of May 31, 2031. This research initiative addresses the critical gap in lung cancer screening (LCS) uptake among high-risk populations by developing and testing interventions specifically designed for emergency department (ED) settings. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $769,260 under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic ductal adenocarcinoma (PDAC). The project, which commenced on April 10, 2026, and concludes on March 31, 2028, focuses on delineating how remodeling of tumor-immune interactions contributes...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan a $669,278 Project Grant (CFDA 93.395: Cancer Treatment Research) effective June 1, 2026, through May 31, 2031, to develop and validate a novel microbial-based cancer therapy platform. The research focuses on engineering nonpathogenic, tumor-tropic Escherichia coli bacteria to display membrane-anchored immune cytokines, specifically decoy-resistant interleukin-18 (DR-18), to enhance localized...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Research Foundation for the State University of New York $410,545 under the Cancer Treatment Research program (CFDA 93.395) for a two-year project period from May 1, 2026, through April 30, 2028. This project grant supports research to assess efflux transport mechanisms, pharmacokinetics, and systems pharmacology impacts on monomethyl auristatin E (MMAE)-induced neurotoxicity in patients receiving antibody-drug conjugate...